En Carta Diagnostics

En Carta Diagnostics

DeepTechParis, France· B2C

En Carta Diagnostics is a Paris-based deeptech startup focused on developing home-based molecular diagnostic tools for Lyme disease and sexually transmitted infections. The company aims to provide results within 30 minutes, matching the precision of laboratory PCR tests, and has recently achieved FDA Breakthrough Device Designation.

$5.3MVisit website ↗

🏆 Featured in Datapile’s Q3 2026 France Funding Report

Read the Q3 2026 France report →
Add this badge to your site
Featured in Datapile’s Q3 2026 France Funding Report
<a href="https://datapile.co/reports/q3-2026-france-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 France Funding Report</a>

Funding history

  1. $5.3M2026-07-12
    Source: news.google.com ↗

Founder

Guillaume Horreard
Guillaume Horreard
Co-founder

Investors in En Carta Diagnostics

Backers from this company's tracked funding rounds.

  • Blue Forest Ventures
  • Ring Capital
  • CentraleSupélec Venture
  • 50 Partners Health
  • Bpifrance

More DeepTech companies

Recently funded startups in the same category.

Related on Datapile